Genmab — Juni 2019

[E_L]

sure. i wish i had all the answers, but unfortunately i think we have to be a bit more patient

[polle1]

Thats the only thing that doesn't change : our PATIENCE

[E_L]

or lack of it

[polle1]

No further comments

[Sukkeralf]

E L whats your take on Genmab doing investor presentation but for the first time in a very long time or maybe first time ever no webcasts - thats very strange and hard to believe just is a coincidence?

[Sukkeralf]

And with 3 out 4 investor presentations being involved in Genmabs Nasdaq listing

[E_L]

i am not sure you should read too much into it; we had some presentations that were not made public. Also, they just changed their investor relations team, that could be a factor

[E_L]

they have given us a lot of info in the last meetings and Q1 review, i doubt there will have been more in those presentations we havent seen

[E_L]

not sure what your 2nd question is?

[Sukkeralf]

Only one question - the next was just information !

[Solsen]

Roadshow before IPOs is usual

[E_L]

ok

[Solsen]

Novod med en frisk melding fra fronten:

[Solsen]

Patient recruitment in one arm of the DREAMM6 study with GSK's GSK916 anti-BCMA ADC in MM put on temporary hold by FDA – to resume recruitment in July

[Sukkeralf]

nice Solsen

[E_L]

yes, we'll see a roadshow, but i doubt we will see those presentations either?

[Solsen]

Det skulle være Revlimid armen, der er ramt af neutropenia dødsfald

[Sukkeralf]

The worry part of this is not becasue of stock going down - but that sparkels it ! Its mostly because Genmab suddenly asks for money and they suddenly havent talekd about that.

[E_L]

offcourse. it is very unpleasant. and i certainly hope we get clarification, but until we do, i can not judge if it is a + or a - .

[E_L]

i can only judge the Nasdaq listing, as that is a certain fact now, and that is a + to me.